Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedApr 12, 2026
DataAggregated Company Financials
Companies59
  • 7D2.7%
  • 3M-16.5%
  • 1Y12.8%
  • YTD-15.6%

The Pharma industry is up 2.7% in the last week, with Caliway Biopharmaceuticals up 17%. In the same time, Bora Pharmaceuticals was down 8.4%. In the last 12 months, the industry was up 13%. Earnings are forecast to grow by 73% annually.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 12 Apr 2026NT$626.5bNT$119.5bNT$20.8b14.8x30.2x5.2x
Tue, 10 Mar 2026NT$676.0bNT$119.3bNT$19.9b15.9x33.9x5.7x
Thu, 05 Feb 2026NT$808.1bNT$119.3bNT$12.4b17.1x65.1x6.8x
Sat, 03 Jan 2026NT$738.7bNT$118.0bNT$12.3b16.8x60.1x6.3x
Mon, 01 Dec 2025NT$773.6bNT$118.0bNT$12.3b17x62.9x6.6x
Wed, 29 Oct 2025NT$778.8bNT$118.3bNT$9.6b15.7x81x6.6x
Fri, 26 Sep 2025NT$820.9bNT$118.3bNT$9.6b16.4x85.5x6.9x
Sun, 24 Aug 2025NT$802.6bNT$118.4bNT$10.3b16.3x77.9x6.8x
Tue, 22 Jul 2025NT$681.5bNT$116.0bNT$14.3b18.4x47.7x5.9x
Thu, 19 Jun 2025NT$655.7bNT$115.9bNT$14.3b18.5x46x5.7x
Sat, 17 May 2025NT$588.0bNT$116.1bNT$13.9b20.4x42.2x5.1x
Mon, 14 Apr 2025NT$518.5bNT$112.8bNT$10.8b18.2x47.9x4.6x
Wed, 12 Mar 2025NT$649.2bNT$113.0bNT$12.7b22.7x51x5.7x
Fri, 07 Feb 2025NT$648.8bNT$109.3bNT$11.4b22.9x56.8x5.9x
Sun, 05 Jan 2025NT$596.2bNT$109.3bNT$11.4b22x52.1x5.5x
Tue, 03 Dec 2024NT$646.0bNT$109.3bNT$11.5b22.2x56.1x5.9x
Thu, 31 Oct 2024NT$627.6bNT$104.7bNT$8.9b26.5x70.2x6x
Sat, 28 Sep 2024NT$651.4bNT$104.7bNT$8.9b25.8x72.8x6.2x
Mon, 26 Aug 2024NT$660.7bNT$104.8bNT$8.9b26.7x73.9x6.3x
Wed, 24 Jul 2024NT$686.2bNT$100.5bNT$6.8b32.1x100.5x6.8x
Fri, 21 Jun 2024NT$661.4bNT$100.4bNT$7.2b30.5x92.4x6.6x
Sun, 19 May 2024NT$635.2bNT$100.3bNT$8.8b28.8x72x6.3x
Tue, 16 Apr 2024NT$703.8bNT$101.5bNT$9.2b26.8x76.3x6.9x
Thu, 14 Mar 2024NT$620.5bNT$100.0bNT$8.8b24.9x70.9x6.2x
Sat, 10 Feb 2024NT$597.8bNT$101.6bNT$8.2b23.4x73.3x5.9x
Mon, 08 Jan 2024NT$581.2bNT$101.9bNT$7.8b24.2x74.6x5.7x
Wed, 06 Dec 2023NT$583.6bNT$101.6bNT$7.7b24.5x76.2x5.7x
Fri, 03 Nov 2023NT$552.0bNT$101.6bNT$9.7b22x57x5.4x
Sun, 01 Oct 2023NT$548.8bNT$101.7bNT$9.6b22x57x5.4x
Tue, 29 Aug 2023NT$532.2bNT$101.7bNT$9.6b21.7x55.3x5.2x
Thu, 27 Jul 2023NT$582.5bNT$98.7bNT$10.1b16.9x57.9x5.9x
Sat, 24 Jun 2023NT$578.4bNT$98.7bNT$10.1b17.1x57.5x5.9x
Mon, 22 May 2023NT$576.6bNT$93.8bNT$9.4b19.3x61.4x6.1x
Wed, 19 Apr 2023NT$591.4bNT$91.6bNT$8.6b22.6x69x6.5x
Price to Earnings Ratio

69x


Total Market Cap: NT$591.4bTotal Earnings: NT$8.6bTotal Revenue: NT$91.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 64.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 30.2x which is lower than its 3-year average PE of 64.4x.
  • The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 34% per year over the last three years.
  • Revenues for these companies have grown 9.3% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare industry?

TW Market8.78%
Healthcare1.84%
Pharma2.67%
Pharma2.67%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6919 Caliway BiopharmaceuticalsNT$112.0016.9%
+NT$25.5b		88.6%PS4582.5x
6620 Handa PharmaceuticalsNT$72.807.9%
+NT$833.8m		11.5%PE15.3x
1799 Easywell BiomedicalsNT$41.309.5%
+NT$448.9m		-30.2%PS8.6x
6838 Formosa PharmaceuticalsNT$30.8510.4%
+NT$437.8m		37.1%PS490.5x
7878 PharmasagaNT$278.502.2%
+NT$321.2m		n/aPB23.1x

Latest News

7850
NT$21.90
Protect Animal Health
7D
15.0%
1Y
n/a
6919
NT$112.00
Caliway Biopharmaceuticals
7D
16.9%
1Y
88.6%
6620
NT$72.80
Handa Pharmaceuticals
7D
7.9%
1Y
11.5%
4123
NT$39.95
Center Laboratories
7D
-4.2%
1Y
22.4%
4746
NT$51.40
Formosa Laboratories
7D
-7.6%
1Y
-9.5%
6472
NT$411.50
Bora Pharmaceuticals
7D
-8.4%
1Y
-27.9%

6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power

Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).
6461
NT$18.80
Intech Biopharm
7D
4.2%
1Y
3.6%
4743
NT$52.90
Oneness Biotech
7D
-3.1%
1Y
-8.2%
1271
NT$60.60
SunWay Biotech
7D
-9.7%
1Y
5.6%
1799
NT$41.30
Easywell Biomedicals
7D
9.5%
1Y
-30.2%
6838
NT$30.85
Formosa Pharmaceuticals
7D
10.4%
1Y
37.1%
4105
NT$74.50
TTY Biopharm
7D
1.2%
1Y
6.4%
1789
NT$21.15
ScinoPharm Taiwan
7D
-6.6%
1Y
18.8%
6467
NT$116.00
Taho Pharmaceuticals
7D
-7.6%
1Y
109.4%
7878
NT$278.50
Pharmasaga
7D
2.2%
1Y
n/a
6535
NT$139.00
Lumosa Therapeutics
7D
-2.5%
1Y
-9.4%